Abstract:10553 Background: Cancer-specific therapy requires the identification of the tumor origin. Detecting cancer and identifying the tumor origin in early stage can improve the survival and prognosis of cancer patients. However, early diagnosis of cancer is challenging as the early symptoms of cancer are mild or even absent. In order to improve the diagnostic efficacy and the patient compliance, we developed a two-stage model for cancer diagnosis and tissue of origin (TOO) classification, using DNA methylation profile evaluated through non-invasive blood-based testing as biomarker. Methods: cfDNA samples from 302 healthy and 598 cancer patients of 8 cancer types (colorectal, lung, liver, pancreatic, gastric, esophagus, breast and ovarian) were sequenced by our in-house-designed DNA methylation panel and randomly split into a training dataset (213:426) and a testing dataset (89:172). The testing dataset was reserved to evaluate the performance of models and would not be used during the feature selection and model development process. Methylation levels of cfDNA samples were measured by the methylated fragment ratios (MFRs) in methylated-correlated blocks (MCBs). We first selected pan-cancer markers by comparing the MFR values of MCBs between the healthy and the diseased individuals and developed a binary classifier (hyper-methylation score). Sample correctly predicted by the hyper-methylation score in the cancer group were then used for TOO marker selection and model fitting. TOO biomarkers were obtained by a series of pairwise comparisons of MFR values between any two cancer types. A deconvolution model was built to estimate the composition of ctDNA, which implied the tumor origin. Results: The hyper-methylation score model based on 135 MCB biomarkers achieved an area under the curve (AUC) of 0.89 in the training dataset and 0.85 in the testing dataset. Under a specificity of 94.8%, sensitivity was 66.2% in the training dataset. Using the 282 cases successfully being predicted, 583 TOO markers were selected to build the deconvolution model. In the testing dataset, the specificity was 95.5%, and the overall sensitivity was 66.3%. With increasing stage, sensitivity increased in all cancer types: 34.6%, 57.1%, 62.5% and 84.8% in stage I, II, III and IV respectively. In stage I-III, sensitivity was 52.3%. TOO classes were predicted in the 114 true positives from the hyper-methylation score model, producing a top 1 accuracy (true class matched the most probable class) of 75.4% and a top 2 accuracy (true class matched the first or the second most probable class) of 84.2%. Top 1 accuracy was 71.1% in stage I-III, vs. 84.0% in stage IV. Top 2 accuracy was 82.2% in stage I-III, vs. 90.0% in stage IV. Conclusions: Our cfDNA-based epigenetic method achieved outstanding performance either in pan-cancer detection or in TOO classification, and is a promising tool for early-stage cancer diagnosis.

DNA methylation profiling to determine the primary sites of metastatic cancers using formalin-fixed paraffin-embedded tissues

90-gene signature assay for tissue origin diagnosis of brain metastases

A Fast, Affordable, and Minimally Invasive Diagnostic Test for Cancer of Unknown Primary Using DNA Methylation Profiling

Validation of a 90-Gene Assay for Tissue Origin Diagnosis of Brain Metastases.

Abstract 4331: Machine learning-based classification of tissue origin of cancer using methylation profiles

A new parsimonious method for classifying Cancer Tissue-of-Origin Based on DNA Methylation 450K data

Identifying primary site of lung-limited Cancer of unknown primary based on relative gene expression orderings

DNA Methylation Signatures Predicting Liver Metastasis of Colorectal Cancer: A Proof-of-concept Pilot Study.

Identification of DNA methylation biomarkers for risk of liver metastasis in early-stage colorectal cancer

A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary

Identification of the origin of brain metastases based on the relative methylation orderings of CpG sites

An ultrasensitive approach for cancer screening and tissue of origin prediction based on targeted methylation sequencing of cell-free DNA.

Data Independent Acquisition-Mass Spectrometry (Dia-Ms)-based Comprehensive Profiling of Bone Metastatic Cancers Revealed Molecular Fingerprints to Assist Clinical Classifications for Bone Metastasis of Unknown Primary (BMUP).

Tissue of origin prediction for cancer of unknown primary using a targeted methylation sequencing panel

Head and neck cancer of unknown primary: unveiling primary tumor sites through machine learning on DNA methylation profiles

DNA Methylation Markers for Diagnosis and Prognosis of Common Cancers.

PathMethy: an interpretable AI framework for cancer origin tracing based on DNA methylation

Development and Clinical Validation of a 90-Gene Expression Assay for Identifying Tumor Tissue Origin

Genome wide identification of novel DNA methylation driven prognostic markers in colorectal cancer

Evaluating DNA Methylation, Gene Expression, Somatic Mutation, and Their Combinations in Inferring Tumor Tissue-of-Origin

Prediction of brain metastasis development with DNA methylation signatures